Class: Antiallergic Agents
- Histamine H1-receptor Antagonists
ATC Class: S03AA07
VA Class: OP900
Chemical Name: 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzimidazole fumerate (1:2)
Molecular Formula: C17H26N4O•2C4H4O4
CAS Number: 87233-62-3
Relatively selective histamine H1-receptor antagonist; a benzimidazole derivative.
Uses for Emedastine
Symptomatic relief of allergic conjunctivitis.
Emedastine Dosage and Administration
Apply topically to the eye as an ophthalmic solution. Not for injection or oral use.
Remove soft contact lenses prior to administration of each dose (since benzalkonium chloride preservative may be absorbed by the lenses); may reinsert lenses 10 minutes after administration if eyes are not red.
If more than one topical ophthalmic drug is used, administer the drugs at least 5 minutes apart.
Avoid contamination of the solution container.
Do not use if solution is discolored.
Available as emedastine difumarate; dosage expressed in terms of emedastine.
Children ≥3 years of age: 1 drop of a 0.05% solution in the affected eye(s) up to 4 times daily.
1 drop of a 0.05% solution in the affected eye(s) up to 4 times daily.
Cautions for Emedastine
Known hypersensitivity to emedastine or any ingredient in the formulation.
Distributed into milk in rats following oral administration; not known whether distributed into human milk following topical application to the eye. Use with caution.
Safety and efficacy not established in children <3 years of age.
Adverse effect profile in children 3–16 years of age is similar to that in individuals ≥17 years of age.
No substantial differences in safety and efficacy relative to younger adults.
Common Adverse Effects
Interactions for Emedastine
No formal drug interaction studies to date.
Limited systemic exposure following topical application to the eye; plasma concentrations usually are undetectable.
Metabolized in the liver principally to 5- and 6-hydroxyemedastine following oral administration; metabolites appear to undergo further oxidation to form 5′-oxo analogs.
44% of an oral dose is recovered in urine within 24 hours.
3–4 hours following oral administration.
Tightly closed bottle at 4–30°C.
Inhibits the histamine-stimulated conjunctival vascular permeability response in a concentration-dependent manner.
Potency is about 100, 357, or 5813 times that of levocabastine, pheniramine, or antazoline, respectively, on a molar basis.
Advice to Patients
Importance of learning and adhering to proper administration techniques to avoid contamination of the solution container.
Importance of removing soft contact lenses prior to administration of each dose. Delay reinsertion for 10 minutes after administration if eyes are not red; do not wear contact lenses if eye(s) are red. Not indicated for contact lens-related irritation.
Importance of administering different topical ophthalmic preparations at least 5 minutes apart.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs as well as any concomitant illnesses.
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
0.05% (of emedastine)
Emadine (with benzalkonium chloride)
AHFS DI Essentials™. © Copyright 2022, Selected Revisions July 1, 2005. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
More about emedastine ophthalmic
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug class: ophthalmic antihistamines and decongestants
- Other brands